IMPROVED PREDICTIVE VALUE FOR SUSTAINED IMMUNE CONTROL IN PEGINTERFERON ALFA-2A (40KD) (PEGASYS)-TREATED HBEAG-POSITIVE PATIENTS USING COMBINED HBSAG AND HBV DNA LEVELS AT WEEK 24

被引：2
|
作者：
Piratvisuth, T. [1 ]
Chan, H. L. Y. [2 ]
Marcellin, P. [3 ,4 ]
Wat, C. [5 ]
Regep, L. [6 ]
Messinger, D. [7 ]
Kapprell, H. -P. [8 ]
Lu, Z. M. [9 ]
Luo, K. X. [10 ]
机构：
[1] Prince Songkla Univ, Songklanagarind Hosp, NKC Inst Gastroenterol & Hepatol, Dept Internal Med, Hat Yai, Thailand
[2] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China
[3] Univ Paris Diderot, Serv Hepatol, Clichy, France
[4] Univ Paris Diderot, INSERM CRB3 U773, Clichy, France
[5] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[6] F Hoffmann La Roche, Basel, Switzerland
[7] IST GmbH, Mannheim, Germany
[8] Abbott GmbH & Co KG, Wiesbaden, Germany
[9] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Infect Dis, Shanghai, Peoples R China
[10] So Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)60551-0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
538
引用
收藏
页码：S213 / S214
页数：2
相关论文
共 50 条
  • [31] EARLY PREDICTION OF SUSTAINED RESPONSE TO PEGINTERFERON ALFA-2A IN HBEAG-NEGATIVE PATIENTS: THE ROLE OF ON-TREATMENT HBSAG AND HBV DNA LEVELS
    Rijckborst, V.
    Hansenu, B. E.
    Cakaloglu, Y.
    Ferenci, P.
    Tabak, F.
    Akdogan, M.
    Simon, K.
    Akarca, U. S.
    Flisiak, R.
    Verhey, E.
    van Vuuren, A. J.
    Boucher, C. A. B.
    ter Borg, M. J.
    Janssen, H. L. A.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S4 - S5
  • [32] HBV-DNA and infected hepatocytes dynamics in HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2a (40KD) (PEGASYS®), lamivudine, or PEGASYS® plus lamivudine combination therapy using a new bio-mathematical model
    Colombatto, P
    Bizzarri, R
    Civitano, L
    Oliveri, F
    Bonino, F
    Germanidis, G
    Farci, P
    Kitis, G
    Hadziannis, S
    Choudhury, S
    Gieschke, R
    Zahm, F
    Brunetto, M
    HEPATOLOGY, 2004, 40 (04) : 666A - 667A
  • [33] Week 12 EVR predicts EOT in CHC genotype 4 patients treated with peginterferon alfa-2a (40KD)/RBV
    Shobokshi, O
    Serebour, FE
    Skakni, L
    Al-Jasser, N
    Tantawi, AO
    Sabah, A
    Dinish, T
    Al-Quaiz, M
    Qahtani, K
    Sandokji, A
    Al-Blowi, A
    Al-Karawi, M
    Al-Kayyal, B
    Al-Momen, S
    Akbar, H
    Ayoola, A
    El-Hazmi, M
    Humaida, A
    El-Hazmi, I
    Eissa, H
    Khawajah, F
    Al-Khalifa, M
    JOURNAL OF HEPATOLOGY, 2003, 38 : 172 - 172
  • [34] Treatment with Peginterferon alfa-2a (40KD) (PEGASYS®) results in improved rates of response compared to conventional interferon in patients with HBeAg positive chronic hepatitis B harboring HBV gentoypes B or 'difficult-to-treat' genotype
    Cooksley, WGE
    Lai, MY
    Piratvisuth, T
    Wang, YJ
    Mahachai, V
    Chao, YC
    Tanwandee, T
    Chutaputti, A
    Chang, WY
    Zahm, FE
    Pluck, N
    JOURNAL OF HEPATOLOGY, 2003, 38 : 25 - 25
  • [35] ON-TREATMENT MONITORING OF HBsAg LEVELS TO PREDICT RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B
    Lau, G. K. K.
    Marcellin, P.
    Brunetto, M.
    Piratvisuth, T.
    Kapprell, H. -P
    Messinger, D.
    Popescu, M.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S333 - S333
  • [36] Genotype and baseline viremia predict virologic relapse in patients treated with peginterferon alfa-2a (40KD) (Pegasys®) alone and in combination with ribavirin.
    Zeuzem, S
    Balan, V
    Sette, H
    Fried, MW
    Jensen, DM
    Pastore, G
    Marcelin, P
    Sedarati, F
    HEPATOLOGY, 2002, 36 (04) : 580A - 580A
  • [37] A predictive tool for selecting HBeAg-positive chronic hepatitis B patients who have a high probability of HBV DNA suppression and HBeAg seroconversion with peginterferon alfa-2a
    Chan, Henry Lik-Yuen
    Papatheodoridis, George V.
    Messinger, Diethelm
    Bakalos, George
    Lampertico, Pietro
    HEPATOLOGY, 2014, 60 : 1108A - 1108A
  • [38] Peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B:: Results from a large, multinational study.
    Lau, G
    Piratvisuth, T
    Luo, KX
    Marcellin, P
    Thongasawat, S
    Cooksley, G
    Gane, E
    Fried, M
    Chow, WC
    Paik, SW
    Chang, WY
    Berg, T
    Flisiak, R
    Zahm, F
    Pluck, N
    HEPATOLOGY, 2004, 40 (04) : 171A - 171A
  • [39] Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy for HBEAG-negative chronic hepatitis B
    Marcellin, P
    Bonino, F
    Lau, GY
    Farci, P
    Yurdaydin, C
    Piratvisuth, T
    Jin, R
    Gurel, S
    Hadziyannis, S
    Lu, ZM
    Popescu, M
    HEPATOLOGY, 2005, 42 (04) : 580A - 580A
  • [40] REFINED PREDICTION OF WEEK 12 RESPONSE AND SVR BASED ON THE VIROLOGICAL RESPONSE AT WEEK 4 IN HCV GENOTYPE 1 PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) AND RIBAVIRIN (COPEGUS®)
    Marcellin, Patrick
    Reau, Nancy
    Ferenci, Peter
    Jensen, Donald M.
    HEPATOLOGY, 2008, 48 (04) : 1136A - 1136A
12345